Merck Comprehensive Income 2010-2024 | MRK

Merck comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
  • Merck comprehensive income for the quarter ending September 30, 2024 was $-5.371B, a 9.26% increase year-over-year.
  • Merck comprehensive income for 2023 was $-5.161B, a 8.24% increase from 2022.
  • Merck comprehensive income for 2022 was $-4.768B, a 7.65% increase from 2021.
  • Merck comprehensive income for 2021 was $-4.429B, a 33.24% decline from 2020.
Merck Annual Comprehensive Income
(Millions of US $)
2023 $-5,161
2022 $-4,768
2021 $-4,429
2020 $-6,634
2019 $-6,193
2018 $-5,545
2017 $-4,910
2016 $-5,226
2015 $-4,148
2014 $-4,323
2013 $-2,197
2012 $-4,682
2011 $-3,132
2010 $-3,216
2009 $-2,767
Merck Quarterly Comprehensive Income
(Millions of US $)
2024-09-30 $-5,371
2024-06-30 $-5,361
2024-03-31 $-5,274
2023-12-31 $-5,161
2023-09-30 $-4,916
2023-06-30 $-4,900
2023-03-31 $-4,883
2022-12-31 $-4,768
2022-09-30 $-4,743
2022-06-30 $-4,327
2022-03-31 $-4,369
2021-12-31 $-4,429
2021-09-30 $-4,590
2021-06-30 $-4,628
2021-03-31 $-6,622
2020-12-31 $-6,634
2020-09-30 $-6,383
2020-06-30 $-6,393
2020-03-31 $-6,391
2019-12-31 $-6,193
2019-09-30 $-5,390
2019-06-30 $-5,362
2019-03-31 $-5,346
2018-12-31 $-5,545
2018-09-30 $-5,151
2018-06-30 $-5,122
2018-03-31 $-5,060
2017-12-31 $-4,910
2017-09-30 $-4,945
2017-06-30 $-5,094
2017-03-31 $-5,080
2016-12-31 $-5,226
2016-09-30 $-4,252
2016-06-30 $-4,086
2016-03-31 $-4,194
2015-12-31 $-4,148
2015-09-30 $-4,573
2015-06-30 $-4,332
2015-03-31 $-4,167
2014-12-31 $-4,323
2014-09-30 $-2,998
2014-06-30 $-2,444
2014-03-31 $-2,179
2013-12-31 $-2,197
2013-09-30 $-4,698
2013-06-30 $-4,760
2013-03-31 $-4,629
2012-12-31 $-4,682
2012-09-30 $-3,040
2012-06-30 $-3,126
2012-03-31 $-3,217
2011-12-31 $-3,132
2011-09-30 $-2,713
2011-06-30 $-2,776
2011-03-31 $-3,170
2010-12-31 $-3,216
2010-09-30 $-3,490
2010-06-30 $-4,659
2010-03-31 $-3,572
2009-12-31 $-2,767
2009-09-30 $-2,675
2009-06-30 $-2,550
2009-03-31 $-2,473
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $250.889B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $710.098B 73.55
Novo Nordisk (NVO) Denmark $471.460B 34.00
Johnson & Johnson (JNJ) United States $373.591B 15.15
AbbVie (ABBV) United States $312.696B 16.46
Novartis AG (NVS) Switzerland $213.148B 14.17
AstraZeneca (AZN) United Kingdom $203.493B 17.32
Pfizer (PFE) United States $145.358B 9.94
Sanofi (SNY) $122.526B 11.10
Innoviva (INVA) United States $1.199B 9.97